Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-08-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
第三届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding decisions made at the 31st meeting of the 3rd board. It includes approval of the 2017 half-year report and a special report on the use of raised funds, as well as approval of a strategic cooperation agreement amendment. The document does not contain the actual half-year financial report or detailed financial data but references that the full report is available on the designated disclosure website. The document is relatively short (1667 characters) and serves as an announcement of board resolutions and approvals rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and approvals.
2017-08-14 Chinese
第三届监事会第十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Quantum Hi-Tech (China) Biological Co., Ltd. regarding the approval of the 2017 semi-annual report and a special report on the use of raised funds. It is a formal meeting resolution notice confirming the review and approval of these reports, not the reports themselves. The document is short (946 characters) and does not contain the actual financial data or full report content, but rather the meeting decisions about these reports. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and formal meeting resolutions that do not fit other categories.
2017-08-14 Chinese
独立董事关于第三届董事会第三十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the 31st meeting of the third board of directors. It discusses compliance with regulations on related party transactions, external guarantees, and the use of raised funds for the first half of 2017. The document references regulatory notices and governance rules but does not contain full financial statements or detailed financial data. It is a formal opinion related to board matters rather than a full annual or interim report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters.
2017-08-14 Chinese
2017年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "量子高科（中国）生物股份有限公司 2017 年半年度报告全文" which translates to "Quantum Hi-Tech (China) Biological Co., Ltd. 2017 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, business overview, risk factors, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes actual financial figures for the half-year period, detailed business and financial analysis, and management commentary. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2017-08-14 Chinese
关于变更《阿力果战略合作协议》的补充公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a supplemental notice about changes to a strategic cooperation agreement. It details the background, execution, and impact of the changes to the agreement, including sales performance and future plans. The document does not contain financial statements or detailed financial data but rather provides an update on a contractual relationship and its implications. It is not an annual or interim report, earnings release, or audit report. It is also not a regulatory filing or certification. The document is a formal announcement about a business cooperation agreement change, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2017-08-08 Chinese
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It discusses the stock suspension, ongoing regulatory review, and the need for further approvals. The document does not contain financial statements or detailed financial data but is a regulatory update about the status of a restructuring process and stock suspension. It is relatively short (1838 characters) and serves as a formal announcement of ongoing regulatory and procedural matters rather than a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-08-07 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.